Ling Xu

机构：Peking University · ORCID：0009-0000-3422-7623

发表论文 205 篇 · 总被引 1631 次 · h-index 24

代表论文

• XMT-2056, a HER2-Directed STING Agonist Antibody–Drug Conjugate, Induces Innate Antitumor Immune Responses by Acting on Cancer Cells and Tumor-Resident Immune Cells (2025 · Clinical Cancer Research · 被引 45)
• Assessing arterial stiffness using characteristics of Korotkoff sounds (2026 · Frontiers in Cardiovascular Medicine · 被引 1)
• Efficacy and safety of Chinese herbal medicine granules plus chemotherapy in patients with EGFR-mutated advanced lung adenocarcinoma post-progression on first-line EGFR-TKI: study protocol for a multicenter, double-blind, randomized controlled trial (2025 · BMC Complementary Medicine and Therapies · 被引 1)
• Phthalates promote lenvatinib resistance in hepatocellular carcinoma through the HPX-MAPK pathway (2025 · Ecotoxicology and Environmental Safety · 被引 1)
• Data from XMT-2056, a HER2-Directed STING Agonist Antibody–Drug Conjugate, Induces Innate Antitumor Immune Responses by Acting on Cancer Cells and Tumor-Resident Immune Cells (2025 · 被引 1)
• Abstract 4746: PLB-001, a novel anti-dll3 ADC with topoisomerase 1 inhibitor-based linker-payload for treatment of SCLC (2025 · Cancer Research · 被引 1)